STOCK TITAN

Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Gilead Sciences announced a $4.5 million funding initiative aimed at improving health outcomes for Black Americans in the Southern United States. This collaboration with the Satcher Health Leadership Institute and Xavier University focuses on addressing inequities in HIV care. The funds will support efforts in Atlanta, Baton Rouge, and New Orleans over three years, enhancing access to culturally appropriate care, training, and understanding COVID-19's impact on healthcare delivery. This initiative aligns with Gilead's broader strategy to advance health equity.

Positive
  • Gilead's $4.5 million funding demonstrates a commitment to address health inequities for Black Americans.
  • Collaboration with reputable institutions like the Satcher Health Leadership Institute and Xavier University enhances credibility.
  • The initiative targets critical gaps in HIV care access in major Southern cities.
Negative
  • None.

Gilead Will Provide $4.5 Million in Funding to Help Improve Health Outcomes for Black Americans in the Southern United States

– Investment Reflects Gilead’s Broad and Ongoing Commitment to Advancing Health Equity –

FOSTER CITY, Calif. & ATLANTA & NEW ORLEANS--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new health equity collaboration with the Satcher Health Leadership Institute (SHLI) at Morehouse School of Medicine and the Center for Minority Health and Health Disparities Research and Education (CMHDRE) at Xavier University of Louisiana’s College of Pharmacy. The collaboration is focused on addressing the inequities in HIV care for Black communities in the Southern United States. Gilead has a broad and long-standing commitment to advancing global health equity, which it regards as critical to helping to end the HIV epidemic and improving health outcomes for all. The company’s health equity strategy focuses on collaborating with organizations that reach underrepresented and disproportionately impacted communities.

Research shows that inequities drive higher rates of HIV infection, as well as worse HIV clinical outcomes among Black Americans. The COVID-19 pandemic has further highlighted and exacerbated such health inequities, especially in the Southern United States. SHLI and CMHDRE are at the forefront of efforts to improve access to HIV care for Black communities in the Southern U.S. region. Gilead will award a total of $4.5 million in funding over a three-year period to support their work in three cities: Atlanta, Baton Rouge, La., and New Orleans.

The partnership between SHLI and CMHDRE, with support from Gilead, is intended to close critical gaps in care by:

  • Increasing understanding of the impact of COVID-19 on the healthcare delivery system in the Black community
  • Realigning HIV services to reflect the impact of the COVID-19 pandemic
  • Providing training focused on culturally appropriate HIV care, inclusive of stigma-reducing strategies
  • Increasing access to, and utilization of, culturally appropriate care for Black people impacted by the HIV epidemic

“Gilead knows that scientific innovation has the most impact on patients when we help remove societal barriers to care, such as discrimination and stigma. We are committed to investing in organizations, community leaders and experts working to address the underlying determinants of health outcomes,” said Rashad Burgess, Vice President of Advancing Health and Black Equity, Gilead Sciences. “This collaboration will focus on the barriers that are most prevalent in Black communities and help increase access to HIV care to produce better outcomes for Black people.”

“Though the COVID-19 pandemic was a setback to the American healthcare system overall, we must bring to the forefront disproportionately impacted communities who were already historically marginalized prior to the pandemic, including people living with HIV,” said Daniel E. Dawes, J.D., Executive Director, Satcher Health Leadership Institute at Morehouse School of Medicine, and author of The Political Determinants of Health. “The Satcher Health Leadership Institute will collaborate with Gilead and Xavier University of Louisiana to ensure these communities are not an afterthought.”

“Xavier's Center for Minority Health and Health Disparities Research and Education in the College of Pharmacy is proud to partner with Gilead and the Satcher Health Leadership Institute at Morehouse School of Medicine for such an important initiative,” said Dr. Kathleen Kennedy, Dean of Xavier University of Louisiana's College of Pharmacy. “Xavier is a top producer of African Americans with a Doctor of Pharmacy degree, and we instill in our graduates the mission of Xavier and the desire to serve the underserved with an effort to mitigate health disparities for underrepresented communities.”

This latest collaboration is part of Gilead’s broader health equity strategy to support community organizations across the globe in addressing social determinants of health. A recent report commissioned by Gilead, “HIV In The Time of COVID-19: Leaving No-One Behind to Truly End the HIV Epidemic,” details a broad range of barriers to health equity including social and economic factors. While predictors of health outcomes such as race, ethnicity and gender have long existed, the COVID-19 pandemic has exacerbated health inequities, especially for marginalized communities and those affected by HIV. Gilead is increasing investment to address these underlying inequities highlighted by the intersection of the two health crises.

Other Gilead programs that address health equity include the COMPASS Initiative®, a ten-year, $100 million commitment toward addressing HIV/AIDS inequities in the U.S. South, which continues to challenge the structural barriers that are most prevalent in Black communities. Gilead’s Zeroing In™ program supports communities in 41 countries that have been hit doubly hard by HIV and the COVID-19 pandemic. Gilead also created a $10 million Racial Equity Community Impact Fund to support organizations fighting the racial inequities that affect Black communities. In its most recent report, the Funders Concerned About AIDS named Gilead the number one overall philanthropic funder of HIV/AIDS programs.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Gilead has promoted equity, particularly healthcare equity, since the company brought its first therapies to the market. Through global partnerships, Gilead’s medicines today reach millions of people in low- and middle-income countries around the world. In the United States, Gilead has committed more than $100 million over 10 years through the COMPASS Initiative® to community organizations that are working to combat HIV in the U.S. South. In 2020, Gilead launched the Racial Equity Community Impact Fund to support organizations tackling racial inequities affecting Black communities across the United States.

About Satcher Health Leadership Institute at Morehouse School of Medicine

The Satcher Health Leadership Institute (SHLI) at Morehouse School of Medicine aims to be the leading transformational force for health equity in policy, leadership development and research. Rooted in the legacy of its founder, the 16th U.S. Surgeon General, Dr. David Satcher, SHLI's mission is to create systemic change at the intersection of policy and equity by focusing on three priority areas: the political determinants of health, health system transformation, and mental and behavioral health. In conjunction with key strategic partners, SHLI enhances leadership among diverse learners, conducts forward-thinking research on the drivers of health inequities and advances evidence-based policies, all in an effort to contribute to the achievement of health equity for all population groups. Learn more at https://satcherinstitute.org; https://healthequitynetwork.org.

About Xavier University of Louisiana and the Center for Minority Health and Health Disparities Research and Education

Established in 1925, Xavier University of Louisiana is the nation's only historically Black and Catholic University. Located in New Orleans, La., its liberal arts-based programs in diverse fields offer students an unbeatable combination of traditional classroom study, hands-on research, service-learning opportunities and life experiences. Xavier is recognized by the United Negro College Fund (UNCF) as the most successful HBCU in terms of graduates’ upward mobility (2022) and is a nationally recognized leader in STEM and the health sciences. Xavier is known for producing more African American students who graduate from medical schools each year than any other university in the country, and its College of Pharmacy is among the top producers of African American pharmacists. Visit www.xula.edu to learn more.

The Center for Minority Health and Health Disparities Research and Education (CMHDRE) within Xavier’s College of Pharmacy was founded in 2004 to improve the health outcomes of racial and ethnic minorities. The CMHDRE’s mission is to provide the infrastructure required to conduct research and provide community education and clinical services to eliminate health disparities using community engagement and collaborative partnerships. It conducts basic and translational research, provides culturally relevant education and clinical services in the community, and educates current and future health care providers as a forefront leader in the initiative to improve health outcomes for minority populations in the region.

Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.

For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Hayley Home, Gilead

(916) 402-2864

Jareese K. Stroud, SHLI

(404) 752-1907

Regi Reyes, Xavier University of Louisiana

(504) 520-5240

Source: Gilead Sciences, Inc.

FAQ

What is the purpose of Gilead's $4.5 million funding initiative?

The funding aims to improve health outcomes for Black Americans in the Southern United States, focusing on HIV care.

Which areas will benefit from Gilead's collaboration for health equity?

The initiative will support health improvements in Atlanta, Baton Rouge, and New Orleans.

How does Gilead plan to address healthcare inequities in this initiative?

Gilead will fund training, increase understanding of COVID-19's impact, and improve access to culturally appropriate HIV care.

What organizations are involved in Gilead's health equity collaboration?

The collaboration involves the Satcher Health Leadership Institute and Xavier University of Louisiana.

How does this funding align with Gilead's overall business strategy?

The initiative is part of Gilead's broader strategy emphasizing health equity and addressing social determinants of health.

Gilead Sciences Inc

NASDAQ:GILD

GILD Rankings

GILD Latest News

GILD Stock Data

111.79B
1.24B
0.12%
88.41%
1.42%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States of America
FOSTER CITY